Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To determine whether positron emission tomography/computed tomography (PET/CT) and indium In 111 pentetreotide, individually or collectively, predict the outcome of patients with neuroendocrine tumors (NETs).
Methods: Between July 31, 2002, and May 4, 2007, 29 patients with previously diagnosed NETs underwent both PET/CT and indium In 111 pentetreotide imaging at our institution. The images were evaluated for the presence of abnormalities. Clinical outcomes were classified as survival without major morbidities, survival with severe complications of disease, or death. Time to outcome was measured in months from the imaging date to outcome. Kaplan-Meier survival curves were calculated in which patient outcome was compared with results on PET/CT and indium In 111 pentetreotide imaging.
Results: Of the 29 patients, 9 had abnormalities on both PET/CT and indium In 111 pentetreotide imaging. Two patients had abnormal findings on PET/CT but normal findings on pentetreotide imaging. In 5 patients, findings were normal on PET/CT but abnormal on pentetreotide imaging. In 13 patients, normal findings were noted on both PET/CT and pentetreotide imaging. Kaplan-Meier analysis demonstrated a significant survival advantage for patients who had normal findings on PET/CT in comparison with abnormal PET/CT findings (P = .01). Patients with normal findings on indium In 111 pentetreotide imaging had a higher but insignificant survival advantage over those with abnormal results on pentetreotide imaging (P = .08).
Conclusion: For evaluation of NETs, PET/CT and indium In 111 pentetreotide are complementary. Increased metabolic activity in tumor cells is reflected by abnormalities on PET/CT. Patients who had abnormal PET/CT findings had a generally poorer prognosis and a more rapid clinical deterioration than those with normal PET/CT findings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4158/EP08318.ORR1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of Pretargeting and FcRn Binding Abrogation on the Biodistribution of a One-Armed Antibody-Based T Cell Imaging Agent.
Bioconjug Chem
August 2025
Genentech Research and Early Development, Department of Translational Pharmacokinetics and Pharmacodynamics, South San Francisco, California 94080, United States.
Achieving a rapid image contrast is a critical attribute of successful imaging biomarkers of T-cell redirecting cancer immunotherapies, as even small shifts in the cluster of differentiation 8 (CD8) expressing T cell populations can be associated with meaningful therapeutic responses. However, T cell imaging agents, such as one-armed (OA) anti-CD8 monoclonal antibodies, are often limited by high renal uptake and poor resolution against the systemic blood signal. Herein we evaluate antibody pretargeting with and without the abrogation of binding to the neonatal Fc receptor (FcRn) as strategies to enhance the tumor contrast of OA antibodies targeting the minimally internalizing receptor, CD8.
View Article and Find Full Text PDFTowards Dual-Tracer SPECT for Prostate Cancer Imaging Using [Tc]Tc-PSMA-I&S and [In]In-RM2.
Pharmaceuticals (Basel)
July 2025
Ludwig Boltzmann Institute Applied Diagnostics, General Hospital of Vienna, c/o Sekretariat Nuklearmedizin, Währiger Gürtel 18-20, 1090 Vienna, Austria.
: Radiolabeled biomolecules specifically targeting overexpressed structures on tumor cells hold great potential for prostate cancer (PCa) imaging and therapy. Due to heterogeneous target expression, single radiopharmaceuticals may not detect or treat all lesions, while simultaneously applying two or more radiotracers potentially improves staging, stratification, and therapy of cancer patients. This study explores a dual-tracer SPECT approach using [In]In-RM2 (targeting the gastrin-releasing peptide receptor, GRPR) and [Tc]Tc-PSMA-I&S (targeting the prostate-specific membrane antigen, PSMA) as a proof of concept.
View Article and Find Full Text PDFDevelopment of INER-PP-F11N as the Peptide-Radionuclide Conjugate Drug Against CCK2 Receptor-Overexpressing Tumors.
Int J Mol Sci
July 2025
Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei 100226, Taiwan.
This work aimed to evaluate two albumin affinity structure-containing peptide-radionuclide conjugate drugs, INER-PP-F11N-1 and INER-PP-F11N-2, for the diagnosis/treatment of cholecystokinin receptor subtype 2 (CCK2R)-overexpressing cancers. We developed In-111- and Lu-177-labeled INER-PP-F11N radiopharmaceuticals and compared them with the current PP-F11N to investigate metabolic stability, biodistribution, SPECT/CT imaging, and therapeutic responses in CCK2R-expressing tumor xenograft mice. The metabolic stability of [In]In/[Lu]Lu-INER-PP-F11N remained above 90% for up to 144 h after labeling, indicating that the compound is highly stable under in vitro conditions.
View Article and Find Full Text PDFPretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in patients with High-Risk B-cell Lymphomas.
Mol Cancer Ther
July 2025
University of Washington / Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance, Seattle, Washington, United States.
Despite new therapies, many patients with NHL relapse and need more effective salvage therapies. This study (NCT02483000) evaluated the safety of B9E9-FP, a tetrameric single-chain anti-CD20-streptavidin fusion protein used in pre-targeted radioimmunotherapy (PRIT), when combined with BEAM and autologous stem cell transplantation (ASCT) for NHL patients. High-risk NHL patients received B9E9-FP on day -17, clearing agent on day -15, and DOTA-biotin (DOTA-Bt) equally divided and labeled with dose-escalated yttrium-90 (90Y), or with indium-111 (111In for imaging) on day -14.
View Article and Find Full Text PDFCalcitonin and procalcitonin measurement after cholecystokinin-2/gastrin receptor agonist stimulation in patients with advanced medullary thyroid cancer: results from the GRAN-T-MTC study.
Endokrynol Pol
June 2025
Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, Poland.
Introduction: Medullary thyroid cancer (MTC) is characterized by overexpression of cholecystokinin-2/gastrin receptors (CCK2R). There are limitations of calcitonin as a tumor marker in MTC diagnosis and prognosis. Procalcitonin is gaining a role as a complementary tumor marker.
View Article and Find Full Text PDF